tetano
Editor, Senior Moderator
Adv Exp Med Biol. 2018 Jun 22. doi: 10.1007/5584_2018_232. [Epub ahead of print]
[h=1]Antibodies to Influenza Virus Hemagglutinin in the 2016/2017 Epidemic Season in Poland.[/h] Hallmann-Szelińska E[SUP]1[/SUP], Cieślak K[SUP]2[/SUP], Kowalczyk D[SUP]2[/SUP], Szymański K[SUP]2[/SUP], Brydak LB[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The aim of the study was to determine the level of antibodies against hemagglutinin of influenza viruses in the sera of 1,050 patients stratified into 7 different age groups during the 2016/2017 epidemic season in Poland. The method consisted of using the hemagglutination inhibition test (HAI). The findings confirmed the presence of anti-hemagglutinin antibodies against the following influenza virus antigens: A/California/7/2009 (H1N1) pdm09, A/Hong Kong/4801/2014 (H3N2), and B/Brisbane/60/2008. The level of anti-hemagglutinin antibodies differed across the age groups investigated, with the highest values in patients aged 10-14 years. We also found that the protection factor was highest for B/Brisbane/60/2008 antigen. It amounted to 72.7% in 10-14-year olds and to 69.3% in both 15-25 and 26-44-year olds. Taking into account a dismally low percentage of vaccinated population in the 2016/2017 epidemic season in Poland, amounting to barely 3.33%, the findings should be interpreted as representing the patients' immune system response to influenza virus infection.
[h=4]KEYWORDS:[/h] Antibodies; Epidemics; Hemagglutinin; Influenza; Protection factor; Vaccine; Virus
PMID: 29931564 DOI: 10.1007/5584_2018_232
[h=1]Antibodies to Influenza Virus Hemagglutinin in the 2016/2017 Epidemic Season in Poland.[/h] Hallmann-Szelińska E[SUP]1[/SUP], Cieślak K[SUP]2[/SUP], Kowalczyk D[SUP]2[/SUP], Szymański K[SUP]2[/SUP], Brydak LB[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The aim of the study was to determine the level of antibodies against hemagglutinin of influenza viruses in the sera of 1,050 patients stratified into 7 different age groups during the 2016/2017 epidemic season in Poland. The method consisted of using the hemagglutination inhibition test (HAI). The findings confirmed the presence of anti-hemagglutinin antibodies against the following influenza virus antigens: A/California/7/2009 (H1N1) pdm09, A/Hong Kong/4801/2014 (H3N2), and B/Brisbane/60/2008. The level of anti-hemagglutinin antibodies differed across the age groups investigated, with the highest values in patients aged 10-14 years. We also found that the protection factor was highest for B/Brisbane/60/2008 antigen. It amounted to 72.7% in 10-14-year olds and to 69.3% in both 15-25 and 26-44-year olds. Taking into account a dismally low percentage of vaccinated population in the 2016/2017 epidemic season in Poland, amounting to barely 3.33%, the findings should be interpreted as representing the patients' immune system response to influenza virus infection.
[h=4]KEYWORDS:[/h] Antibodies; Epidemics; Hemagglutinin; Influenza; Protection factor; Vaccine; Virus
PMID: 29931564 DOI: 10.1007/5584_2018_232